This article is more than 5 years old. Information may no longer be current.
Encore Vision begins enrollment for phase 1/2 study of presbyopia drug
Click Here to Manage Email Alerts
The first patient has been enrolled in Encore Vision’s phase 1/2 trial of EV06, an investigational topical treatment for presbyopia, according to a company press release.
EV06 (lipoic acid choline ester) is a compound being developed to reverse age-related changes in the crystalline lens that result in diminished lens elasticity.
According to the press release, the FDA has cleared the compound’s investigational new drug application “as safe to proceed with the clinical development of EV06.”
The 90-day phase 1/2 study will compare the safety and efficacy of EV06 to placebo in patients 45 to 55 years old with presbyopia. The study will evaluate mean change in distance corrected near visual acuity and best corrected distance visual acuity.
“To have a pharmaceutical company that could effectively reduce dependence on bifocals or reading glasses is truly a groundbreaking approach in the treatment of presbyopia,” Richard L. Lindstrom, MD, said in the release. “If EV06 proves successful in the clinic, this will be a major shift in how we treat the massive presbyopic population.”